Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15703311 | 0.81 | NPC1 (1.00) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4207684 | 0.79 | RAB9A (0.74) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL17268781 | 0.77 | RAB9A (0.74) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4209817 | 0.76 | RAB9A (0.77) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4208731 | 0.75 | PDPK1 (0.56) | PDPK1IDO1PDGFRBKITKDR | |
| SCHEMBL4208111 | 0.74 | RAB9A (0.74) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4213116 | 0.74 | PDPK1 (1.00) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4726461 | 0.74 | RAB9A (0.78) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL3936506 | 0.74 | RAB9A (1.00) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E | |
| SCHEMBL4219771 | 0.72 | RAB9A (0.66) | RAB9ANPC1PDPK1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | RAB9A 3461/4885NPC1 2497/4885PDPK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.